Claims for Patent: 6,624,297

Summary for Patent: 6,624,297

Title:	Compositions for the genetic modification of plants
Abstract:	Methods and compositions for the targeted integration of nucleotide sequences into a plant are provided. Particularly, the present invention is drawn to compositions comprising polynucleotide sequences having the following operably linked components: an intron, a nucleotide sequence of interest, and a terminator region, wherein the polynucleotide sequence comprises one or more recombination sites. The recombination sites are non-identical to one another and one of the recombination sites is contained within the intron.
Inventor(s):	Baszczynski; Christopher L. (Urbandale, IA), Bowen; Benjamin A. (Des Moines, IA), Peterson; David J. (Ames, IA), Tagliani; Laura A. (Ankeny, IA)
Assignee:	Pioneer Hi-Bred International, Inc. (Des Moines, IA)
Application Number:	09/455,050
Patent Claims:	1. An isolated polynucleotide comprising the following operably linked components: an intron and a nucleotide sequence of interest, wherein said intron comprises a first FRT recombination site, wherein said intron is selected from the group consisting of a ubiquitin intron, an ADH intron, and a DnaJ intron. 2. The isolated polynucleotide of claim 1, wherein said polynucleotide further comprises a second FRT recombination site, wherein said first and said second FRT recombination sites are non-identical. 3. The isolated polynucleotide of claim 2, wherein the ubiquitin intron comprises the first intron from a maize ubiquitin gene. 4. The isolated polynucleotide of claim 2, wherein the Adh intron comprises the first intron from a maize Adh gene. 5. The isolated polynucleotide of claim 2, wherein the DnaJ intron comprises the first intron from a maize DnaJ gene. 6. An isolated polynucleotide comprising the following operably linked components: an intron and a nucleotide sequence of interest, wherein said intron comprises a first FRT recombination site and wherein said polynucleotide further comprises a second FRT recombination site, wherein said first and said second FRT recombination sites are non-identical, wherein the non-identical FRT recombination sites are selected from the group consisting of a FRT site and a mutant FRT site, and wherein at least one of the mutant FRT site is selected From the group consisting of FRT 5 (SEQ ID NO:3), FRT 6 (SEQ ID NO:4), and FRT 7 (SEQ ID NO:5). 7. An isolated polynucleotide comprising the following operably linked components: an intron and a nucleotide sequence of interest, wherein said intron comprises a first FRT recombination site, and wherein said first FRT recombination site is selected from the group consisting of a FRT site and a mutant FRT site and said intron is selected from the group consisting of a ubiquitin intron, an ADH intron, and a DnaJ intron. 8. The isolated polynucleotide of claim 7, wherein the mutant FRT site is selected from the group consisting of FRT 5 (SEQ ID NO:3), FRT 6 (SEQ ID NO:4), and FRT 7 (SEQ ID NO:5). 9. An isolated polynucleotide comprising the following operably linked components: an intron and a nucleotide sequence of interest, wherein said intron comprises a first recombination site, wherein said intron is selected from the group consisting of a ubiquitin intron, an ADH intron, and a DnaJ intron. 10. The isolated polynucleotide of claim 9, wherein said isolated polynucleotide further comprises a second recombination site, wherein said first and said second recombination sites are non-identical. 11. The isolated polynucleotide of claim 10, wherein the ubiquitin intron comprises the first intron from a maize ubiquitin gene. 12. The isolated polynucleotide of claim 10, wherein the Adh intron comprises the first intron from a maize Adh gene. 13. The isolated polynucleotide of claim 10, wherein the DnaJ intron comprises the first intron from a maize DnaJ gene. 14. An isolated polynucleotide comprising the following operably linked components: an intron and a nucleotide sequence of interest, wherein said intron comprises a first recombination site, wherein said polynucleotide further comprises a second recombination site, wherein said first and said second recombination sites are non-identical, wherein the non-identical recombination sites are selected from the group consisting of a FRT site, a mutant FRT site, a LOX site, and a mutant LOX site, and wherein at least one of the first or the second recombination sites comprise the mutant FRT site wherein the mutant FRT site is is selected from the group consisting of FRT 5 (SEQ ID NO:3), FRT 6 (SEQ ID NO:4), and FRT 7 (SEQ ID NO:5). 15. An isolated polynucleotide comprising the following operably linked components: an intron and a nucleotide sequence of interest, wherein said intron comprises a first recombination site, wherein said first recombination site is a mutant FRT site selected from the group consisting of FRT 5 (SEQ ID NO:3), FRT 6 (SEQ ID NO:4), and FRT 7 (SEQ ID NO:5).

Details for Patent 6,624,297

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-11-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-11-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-11-18